GW Pharmaceuticals (Nasdaq: GWPH) reported positive results from a second Phase 3 pivotal trial for Epidiolex sending the stock price soaring $18.50 to close at $126.06.
GW Pharmaceuticals reports positive study results
September 26, 2016 at 17:36 PM EDT
